Abbott Laboratories

ABTNYSEHealthcare● Active

$91.25

+$0.18(+0.20%)

Market Cap$158.9B

P/E Ratio—

52W High$139.06

52W Low$81.97

Avg Volume12.7M

Open$90.54

Beta0.62

Free Cash Flow Financials Revenue

Abbott Laboratories (ABT) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ABT · free cash flow · updated Jun 8, 2026

Core FCF metrics

ABT · FCF · TTM · margin & CAGR

Free cash flow was $7.39B for FY2025 (fiscal year ending 2025-12-31), up 16.4% year-over-year The FCF margin was 16.7%. Five-year CAGR stands at +5.3%.

FY2025 Free Cash Flow$7.39B▲ +16.4% YoY

Trailing 12M (TTM)$7.38Btrailing 4 quarters sum

FCF Margin16.7%$7.39B ÷ revenue

3-Year CAGR-1.8%FY2022 → FY2025

5-Year CAGR+5.3%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ABT · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$9.57B(2.17B)$7.39B▲ +16.4%16.7%

FY2024$8.56B(2.21B)$6.35B▲ +25.5%15.1%

FY2023$7.26B(2.20B)$5.06B▼ 35.2%12.6%

FY2022$9.58B(1.78B)$7.80B▼ 9.8%17.9%

FY2021$10.53B(1.89B)$8.65B▲ +51.1%20.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ABT · P/FCF · FCF yield · FCF per share

Abbott Laboratories (ABT) trades at a FCF yield of 4.65% and a price-to-free-cash-flow ratio of 21.6x. FCF per share stands at $4.22, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

4.65%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$4.22

TTM FCF ÷ Shares Outstanding

Price / FCF

x21.6

Share Price ÷ FCF per Share

EV / FCF (TTM)

x25.2

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ABT · cash flow statement · operating / investing / financing

For FY2025, Abbott Laboratories generated $9.57B in operating cash flow and spent 2.17B in capital expenditures, yielding $7.39B in free cash flow.

Operating Activities

+$9.57B

Cash from core business operations

2025-12-31

Investing Activities

−$2.42B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$6.31B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($9.57B) − |CapEx| (2.17B) = FCF ($7.39B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ABT vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Abbott LaboratoriesYOU

ABT

$7.39B+16.4%16.7%

38%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Abbott Laboratories (ABT) reported free cash flow of $7.39B for FY2025 (fiscal year ending 2025-12-31), up 16.4% year-over-year. The FCF margin was 16.7%.

Based on available data, Abbott Laboratories has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $8.65B in FY2021. The 5-year CAGR stands at +5.3%.

Abbott Laboratories's FCF yield is 4.65% and price-to-FCF ratio is 21.6x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ABT free cash flow · 8 questions

Abbott Laboratories free cash flow was $7.39B for FY2025, up 16.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $7.38B.

ABT free cash flowABT FCFABT FCF 2025ABT free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Abbott Laboratories · Abbott Laboratories SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026